Novalar Pharmaceuticals, Inc. Report issue

For profit Phase 3
Founded: San Diego CA United States (2000)
Status: Acquired by Septodont (2000) → now Deproco (2000)

Organization Overview

First Clinical Trial
2003
NCT00154167
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2006

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (1)

phentolamine mesylate (regitine) (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hypesthesia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 1